Social Behavior
Pfizer Appoints Chris Boshoff as New Chief Scientific Officer and President of Research & Development
Pfizer, Chris Boshoff, Chief Scientific Officer, President of Research & Development, Mikael Dolsten, Leadership Changes, Oncology, R&D
BeiGene Secures Long-Term Protection for BRUKINSA with Patent Settlement Until 2037
BeiGene, BRUKINSA, patent settlement, MSN Pharmaceuticals, generic competition, market exclusivity, BTK inhibitor, cancer treatment
Angela Hwang Joins Flagship Pioneering as CEO-Partner and CEO of Metaphore Biotechnologies
Angela Hwang, Flagship Pioneering, Metaphore Biotechnologies, Pfizer, Biotechnology, Leadership Appointment
Roche and Flare Therapeutics Launch $1.8B-Plus Cancer Collaboration Targeting Transcription Factors
Roche, Flare Therapeutics, transcription factors, cancer drugs, oncology, biotech collaboration
Pharmaceutical Giants Eli Lilly and Novo Nordisk Face Challenges Despite Strong Sales Growth
Eli Lilly, Novo Nordisk, Q3 2024 financial results, Obesity drugs, Weight loss therapies, Pharmaceutical industry challenges, Market competition, Supply pressures, Pricing issues
Catalent Misses Revenue Estimates Amid Growing Opposition to Novo Holdings’ $16.5 Billion Acquisition
Catalent, Novo Holdings, Acquisition, Revenue Estimates, Pharmaceutical Market, Competition, FTC, Antitrust
Advancements in Bispecific Antibody Therapies: Recent Deals and Clinical Data on VEGF-Targeting Agents
Bispecific antibodies, VEGF, neovascular age-related macular degeneration (nAMD), cancer therapy, clinical trials, royalty agreements.
FDA Authorizes LumiThera’s Valeda Light Delivery System for Dry AMD Treatment
FDA authorization, Valeda Light Delivery System, dry AMD treatment, photobiomodulation, LumiThera
Pharma’s Future at Stake: Trump’s Victory and Its Implications for Drug Pricing Reform
Donald Trump, Kamala Harris, 2024 Presidential Election, Drug Pricing Reform, Inflation Reduction Act, Medicare Price Negotiations, Pharmaceutical Industry, Biopharma.
European Commission Imposes €463 Million Fine on Teva for Anti-Competitive Practices in MS Drug Market
Teva, European Commission, fine, MS drug, competition tactics, Copaxone, market dominance